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Background. An inverse relationship between cardiovascular risk and levels of vitamin D and omega-3 index may exist. Objectives.
To evaluate the prognostic utility of serum 25-hydroxyvitamin D [25(OH)D] in 871 patients with suspected acute coronary
syndrome (ACS) and to assess the seasonal correlation between 25(OH)D and the omega-3 index in 456 ACS patients from
southwestern Norway. Results. In the univariate analysis the hazard ratio (HR) at 2-year follow-up for all-cause mortality in the
highest as compared to the lowest quartile of 25(OH)D in the total population was 0.61 (95% confidence interval (CI), 0.37–
1.00), 𝑃 = 0.050. At 7-year follow-up, the corresponding HR for all-cause mortality was 0.66 (95% CI, 0.49–0.90), 𝑃 = 0.008,
and for females alone 0.51 (95% CI, 0.32–0.83), 𝑃 = 0.006. Quartile survival did not differ in the multivariable analysis, whereas
25(OH)D < 40 nM (<16 ng/mL) was found to be independently related to mortality. Seasonal differences in 25(OH)D, but not
for the omega-3 index, were noted, and the two biomarkers were positively correlated, especially during winter-spring; Pearson’s
correlation coefficient was 0.358, 𝑃 < 0.001. Conclusion.Vitamin D levels are related to survival, especially in females, and correlate
with the omega-3 index.
1. Introduction
In observational studies vitamin D and n-3 polyunsaturated
fatty acids (PUFA) have been found to be inversely related
to cardiovascular disease (CVD) [1, 2]. Whether these factors
are causal or are simply markers of a generally lower-risk
lifestyle is still unsettled.
Low vitaminD levels have been associatedwith hyperten-
sion, obesity, dyslipidemia, and diabetes mellitus, reflecting
an increased cardiovascular (CV) risk burden [3]. However,
also high levels can be associated with increased total and CV
mortality, as described by a U-shape or reverse J-curve [4–6].
N-3 fatty acids may exert beneficial effects on hemo-
dynamics, lipid metabolism, inflammation, thrombosis, and
ventricular arrhythmias [7]. Fish is the major food source
of long-chain n-3 PUFA and includes eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) [8]. The omega-3
index is a measure of these fatty acids, given as a percentage
of total fatty acids in red blood cell membranes [9].
Vitamin D is mainly synthesized in the skin from 7-
dehydrocholesterol under the influence of sun exposure and
the remaining 10–20% is ingested in the diet in which fatty
fish is a major contributor [10]. The synthesis of vitamin D in
response to ultraviolet B (UVB) radiation in sunlight depends
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on factors such as latitude, altitude, time of year and day-time,
weather, age, skin pigmentation type, clothing, and sunscreen
and is influenced by environment (pollution) and lifestyle
[11]. Conditions such as poor nutrition and chronic illness are
also associated with vitamin D deficiency [12].
The prognostic utility of vitamin D in relation to long-
term CV outcomes has been evaluated in subjects without a
history of CVD, as in the Framingham Offspring study [13]
and in patients with established CVD [14, 15]. We have previ-
ously shown that 2- and 5-year total and cardiac mortality is
decreased in the highest as compared to the lowest quartile
of vitamin D in a coronary chest-pain population living
at altitudes exceeding 1000 meters in subtropical northern
Argentina [16], and this relationship is stronger in females
than in males [17].
The main aim of our study was to evaluate the prognostic
utility of vitamin D measured as serum 25-hydroxyvitamin
D [25(OH)D] in a Norwegian coastal coronary chest-pain
population exposed to temperate sun activity at low altitudes
and with a high consumption of fish as reflected by the
omega-3 index. As a secondary aim, we looked into the
seasonal correlation between 25(OH)D and the omega-3
index in the subjects with troponin-T (TnT) positive values.
2. Methods
Participants in the present analysis belonged to the RACS
study (Risk Markers in the Acute Coronary Syndrome)
(ClinicalTrials.gov NCT00521976), a single-center prospec-
tive observational study designed to evaluate the prognos-
tic utility of serum 25(OH)D (D represents D
2
and D
3
)
status in 871 patients with chest pain and suspected ACS
consecutively admitted to the Stavanger University Hospital
from November 2002 to October 2003. The details of the
RACS study have been published previously [18].Theprimary
outcome in the present study was all-cause mortality at 2-
and 7-year follow-up and the secondary outcomes included
cardiac death and sudden cardiac death (SCD) at 2-year
follow-up, as previously defined [16]. Measurements of the
omega-3 index at admission were previously investigated in
456 of the 471 ACS patients (defined by a peak baseline
TnT value > 0.01 ng/mL) [19]. In this subpopulation we
performed a seasonal (summer-autumn defined as June–
November and winter-spring defined as December–May)
correlation between levels of 25(OH)D and the omega-3
index. 25(OH)D as a prognostic marker was evaluated in
the total population, as well as in subgroups including TnT
positive and TnT negative patients, gender, and vitamin D
deficient subjects (defined as 25(OH)D < 40 nM (16 ng/mL))
[20]. Furthermore, seasonal variations in 25(OH)D were
evaluated in the total population. Data were analyzed in
quartiles of 25(OH)D and as continuous 25(OH)D values
applying univariate and multivariable analyses.
The study was approved by the Regional Board of
Research Ethics and the Norwegian Health Authorities and
conducted in accordance with the Helsinki Declaration of
1971, as revised in 1983. Written informed consent was
obtained from all patients.
Blood samples were drawn immediately following admis-
sion by direct venipuncture of an antecubital vein, applying
a minimum of stasis. A second blood sample for TnT deter-
mination was drawn six hours following the first sample.
Baseline laboratory data for this study included measure-
ments of 25(OH)D
2
, 25(OH)D
3
, TnT, high sensitivity C-
reactive protein (hsCRP), glucose, serum lipids, B-type natri-
uretic peptide (BNP) measured in EDTA (ethylene diamine
tetraacetic acid) plasma, estimated glomerular filtration rate
(eGFR) (calculated by modification in diet in renal disease
(MDRD) formula), and omega-3 index.
TnT was quantified by a cardiac-specific second-genera-
tion troponin T ELISA assay fromRocheDiagnostics, using a
high-affinity cardiac-specific TnT isoform antibody [21]. The
lower detection limit of the assay used is 0.01 ng/mL.
25(OH)D analysis was carried out at the Department of
Medical Biochemistry at Stavanger University Hospital, as
previously described [16].
The omega-3 index (EPA + DEA) content was measured
in packed red blood cells, as previously described by Harris
and von Schacky [9] and by Aarsetoey et al. [19].
2.1. Statistical Analysis. Patients were grouped into quartiles
according to their 25(OH)D levels within the total population
and TnT positive and negative subpopulations as appropriate.
As a sensitivity analysis, selected analyses were conducted
using continuous values instead of quartiles. Approximately
normally distributed variables were given as mean and
standard deviation (SD). The Chi-square test for association
was applied between the 25(OH)D quartiles and categorical
variables at baseline. The one way analysis of variance
(ANOVA) was used to test for equality of means of scale
variables (e.g., age) amongst 25(OH)D quartiles. The hazard
ratios (HR) are presented with 95% confidence interval (CI).
Separate stepwise Cox multivariable proportional hazards
regression models with total death, cardiac death and SCD
as the dependent variable, and 25(OH)D and other variables
as potential independent predictors (listed below) were fitted.
To examine the differences in prognosis between subjects in
the upper quartile(s) versus the lowest quartile of 25(OH)D,
we adjusted for gender, age, smoking, hypertension, index
diagnosis, diabetes mellitus, congestive heart failure (CHF)
(defined byKillip-Kimball class at admission; patients in class
2 to 4 were classified as CHF patients and those in class
1 as non-CHF), history of previous coronary heart disease
(CHD) (i.e., history of either angina pectoris, myocardial
infarction, percutaneous coronary intervention, or coronary
artery bypass graft), hypercholesterolemia/use of statins, TnT
> 0.01 ng/mL, eGFR, hsCRP, BNP, body mass index (kg/m2),
and beta-blockers prior to enrolment. The Kaplan-Meier
product limits were used for plotting times to event with the
equality of the 25(OH)D quartile survival curves assessed by
the log-rank test. Hypothesis two-sided 𝑃 values less than
0.05 are defined as statistically significant.
3. Results
A total of 871 patients (531 men and 340 women) were
enrolled in the RACS study. Ten samples were not available;
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Table 1: Baseline characteristics of the total population arranged according to the quartiles of 25(OH)D.
Characteristics 𝑛 (%) Quartiles of 25(OH)D 𝑃 value
Q1 Q2 Q3 Q4
25(OH)D (nmol/L)∗ 30.5 ± 5.9 45.2 ± 3.4 56.7 ± 3.6 78.6 ± 13.2 <0.001
25(OH)D (ng/mL)∗ 12.2 ± 2.4 18.1 ± 1.4 22.7 ± 1.4 31.4 ± 5.3 <0.001
Age, years∗ 68.9 ± 16.1 69.4 ± 15.6 70.7 ± 13.2 69.3 ± 12.4 0.591
Male, 𝑛 (%) 120 (55.8) 138 (64.2) 127 (58.8) 140 (65.1) 0.150
Smoking status, 𝑛 (%) 0.110
Current smoker, 𝑛 (%) 71 (33.0) 58 (27.0) 46 (21.3) 52 (24.2)
Past smoker, 𝑛 (%) 65 (30.2) 78 (36.3) 83 (38.4) 87 (40.5)
Never smoked, 𝑛 (%) 79 (36.7) 79 (36.7) 87 (40.3) 76 (35.3)
Angina pectoris, 𝑛 (%) 93 (43.3) 90 (41.9) 100 (46.3) 93 (43.3) 0.820
CHF, 𝑛 (%)
Killip Class 2–4 84 (39.1) 48 (22.3) 52 (24.1) 48 (22.3) <0.001
History of previous MI, 𝑛 (%) 82 (38.1) 69 (32.1) 71 (32.9) 66 (30.7) 0.382
CABG, 𝑛 (%) 22 (10.2) 17 (7.9) 26 (12.0) 22 (10.2) 0.564
PCI, 𝑛 (%) 18 (8.4) 21 (9.8) 25 (11.6) 23 (10.7) 0.721
Hypertension, 𝑛 (%) 87 (40.5) 86 (40.0) 96 (44.4) 93 (43.3) 0.746
History of DM 1, 𝑛 (%) 2 (0.9) 2 (0.9) 0 (0.0) 4 (1.9) 0.256
History of DM 2, 𝑛 (%) 38 (17.7) 24 (11.2) 34 (15.7) 15 (7.0) 0.004
STEMI, 𝑛 (%) 30 (14.0) 35 (16.3) 31 (14.4) 32 (14.9) 0.913
TnT release, 𝑛 (%) 117 (54.4) 115 (53.5) 120 (55.6) 115 (53.5) 0.969
eGFR (𝜇mol L−1)∗ 63.5 ± 22.1 61.7 ± 20.8 62.9 ± 20.2 63.0 ± 20.3 0.834
Cholesterol/Statin, 𝑛 (%) 104 (48.4) 105 (48.8) 109 (50.5) 107 (49.8) 0.973
Beta-blocker, 𝑛 (%) 81 (37.7) 78 (36.3) 77 (35.6) 73 (34.0) 0.881
Known CHD, 𝑛 (%) 140 (65.1) 132 (61.4) 142 (65.7) 129 (60.0) 0.537
BMI (kg/m2)∗ 25.7 ± 4.4 26.3 ± 4.7 25.7 ± 4.2 25.0 ± 3.7 0.024
BNP quartiles 0.222
Q1 47 (22.8) 52 (24.8) 44 (21.4) 64 (31.7)
Q2 50 (24.3) 50 (23.8) 60 (29.1) 44 (21.8)
Q3 48 (23.3) 53 (25.2) 54 (26.2) 53 (26.2)
Q4 61 (29.6) 55 (26.2) 48 (23.3) 41 (20.3)
hsCRP quartiles 0.910
Q1 51 (23.7) 52 (24.2) 53 (24.5) 61 (28.4)
Q2 49 (22.8) 50 (23.3) 56 (25.9) 57 (26.5)
Q3 57 (26.5) 57 (26.5) 53 (24.5) 50 (23.3)
Q4 58 (27.0) 56 (26.0) 54 (25.0) 47 (21.9)
∗Mean ± SD.
SD, standard deviation; 25(OH)D, 25-hydroxyvitamin D; CHF, congestive heart failure; MI, myocardial infarction; CABG, coronary artery bypass grafting;
PCI, percutaneous coronary intervention; DM, diabetes mellitus; STEMI, ST-elevation myocardial infarction; TnT, troponin T; eGFR, estimated glomerular
filtration rate; CHD, coronary heart disease; BMI, body mass index; BNP, B-type natriuretic peptide; hsCRP, high sensitivity C-reactive protein.
thus 861 patients (525 men and 336 women) were included in
the present 25(OH)D analysis. Of these, 467 patients (54%)
(305 men and 162 women) were characterized by a TnT
release> 0.01 ng/mL.Mean age in the total patient population
was 69.6 ± 14.4 years (males 66.6 ± 14.3 years and females
74.4 ± 13.1 years). Mean 25(OH)D levels were 52.7 ± 19.1 nM
(21.1±7.6 ng/mL) in the total patient population;males 53.8±
19.3 nM (21.5±7.7 ng/mL) and females 51.0±18.8 nM (20.4±
7.5 ng/mL). Seasonal 25(OH)D levels in all patients were
51.6 ± 18.9 nM (20.6 ± 7.6 ng/mL) during winter-spring and
55.4 ± 19.1 nM (22.2 ± 7.6 ng/mL) during summer-autumn;
𝑃 = 0.007. The seasonal difference was greatest in males
(52.1 nM ± 19.1 nM versus 57.7 nM ± 19.1 nM; 𝑃 = 0.002) and
not significant in women (50.7 nM ± 18.5 nM versus 51.6 nM
± 19.5 nM; 𝑃 = 0.711).
The baseline characteristics according to 25(OH)D quar-
tiles at admission in the total patient population, in the TnT
positive group, and in both genders are shown in Tables 1, 2,
and 3(a)-3(b), respectively.
3.1. 2-Year Follow-Up. At 2-year follow-up, 136 (70 men and
66 women) patients with known 25(OH)D values had died,
84 (62%) of whom died due to a cardiac event, and of these,
25 cases were defined as SCD. In the TnT positive group 104
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Table 2: Baseline characteristics of the TnT positive patient population arranged according to the quartiles of 25(OH)D.
Characteristics 𝑛 (%) Quartiles of 25(OH)D 𝑃 value
Q1 Q2 Q3 Q4
25(OH)D (nmol/L)∗ 30.2 ± 6.2 44.9 ± 3.5 56.6 ± 3.6 78.1 ± 13.2 <0.001
25(OH)D (ng/mL)∗ 12.1 ± 2.5 18.0 ± 1.4 22.6 ± 1.4 31.2 ± 5.3 <0.001
Omega-3 Index∗ 6.1 ± 1.6 6.4 ± 1.6 6.9 ± 1.9 7.5 ± 2.2 <0.001
Age, years∗ 72.5 ± 14.8 72.6 ± 13.5 71.5 ± 13.8 71.2 ± 11.0 0.809
Male, 𝑛 (%) 64 (55.2) 81 (69.2) 73 (62.4) 86 (74.1) 0.015
Smoking status, 𝑛 (%) 0.047
Current smoker, 𝑛 (%) 36 (31.0) 37 (31.6) 35 (29.9) 30 (25.9)
Past smoker, 𝑛 (%) 30 (25.9) 42 (35.9) 35 (29.9) 53 (45.7)
Never smoked, 𝑛 (%) 50 (43.1) 38 (32.5) 47 (40.2) 33 (28.4)
Angina pectoris, 𝑛 (%) 49 (42.2) 48 (41.0) 52 (44.4) 51 (44.0) 0.949
CHF, 𝑛 (%)
Killip Class 2–4 56 (48.3) 27 (23.1) 30 (25.6) 32 (27.6) <0.001
History of previous MI, 𝑛 (%) 46 (39.7) 37 (31.6) 35 (29.9) 38 (32.8) 0.413
CABG, 𝑛 (%) 11 (9.5) 7 (6.0) 12 (10.3) 12 (10.3) 0.612
PCI, 𝑛 (%) 9 (7.8) 9 (7.7) 7 (6.0) 10 (8.6) 0.893
Hypertension, 𝑛 (%) 48 (41.4) 47 (40.2) 52 (44.4) 49 (42.2) 0.926
History of DM 1, 𝑛 (%) 0 (0.0) 2 (1.7) 0 (0.0) 4 (3.4) 0.058
History of DM 2, 𝑛 (%) 26 (22.4) 19 (16.2) 19 (16.2) 9 (7.8) 0.023
STEMI, 𝑛 (%) 29 (25.0) 35 (29.9) 30 (25.6) 33 (28.4) 0.813
eGFR (𝜇mol L−1)∗ 59.7 ± 23.2 59.8 ± 22.3 62.5 ± 23.3 63.9 ± 23.5 0.418
Cholesterol/statin, 𝑛 (%) 53 (45.7) 54 (46.2) 52 (44.4) 50 (43.1) 0.967
Beta-blocker, 𝑛 (%) 40 (34.5) 39 (33.3) 35 (29.9) 34 (29.3) 0.793
Known CHD, 𝑛 (%) 80 (69.0) 71 (60.7) 76 (65.0) 72 (62.1) 0.566
BMI (kg/m2)∗ 25.7 ± 4.5 25.9 ± 4.6 25.6 ± 4.3 25.3 ± 3.9 0.714
BNP quartiles 0.778
Q1 15 (13.8) 17 (15.0) 22 (19.5) 23 (21.3)
Q2 24 (22.0) 23 (20.4) 25 (22.1) 24 (22.2)
Q3 26 (23.9) 34 (30.1) 32 (28.3) 26 (24.1)
Q4 44 (40.4) 39 (34.5) 34 (30.1) 35 (32.4)
hsCRP quartiles 0.698
Q1 18 (15.5) 22 (18.8) 19 (16.2) 27 (23.3)
Q2 24 (20.7) 27 (23.1) 31 (26.5) 27 (23.3)
Q3 32 (27.6) 36 (30.8) 36 (30.8) 32 (27.6)
Q4 42 (36.2) 32 (27.4) 31 (26.5) 30 (25.9)
∗Mean ± SD.
SD, standard deviation; 25(OH)D, 25-hydroxyvitamin D; CHF, congestive heart failure; MI, myocardial infarction; CABG, coronary artery bypass grafting;
PCI, percutaneous coronary intervention; DM, diabetes mellitus; STEMI, ST-elevation myocardial infarction; TnT, troponin T; eGFR, estimated glomerular
filtration rate; CHD, coronary heart disease; BMI, body mass index; BNP, B-type natriuretic peptide; hsCRP, high sensitivity C-reactive protein.
patients with known 25(OH)D values died: 71 (68%) due to a
cardiac event, including 21 sudden cardiac deaths.
In the univariate quartile analysis of all-cause mortality
in the total population and in the TnT positive patient
population, theHRs for 25(OH)D in the highest quartile (Q4)
as compared to the lowest quartile (Q1) were 0.61 (95% CI,
0.37–1.00), 𝑃 = 0.050, and 0.59 (95% CI, 0.33–1.04), 𝑃 =
0.067, respectively. No difference in HR was found between
25(OH)D quartiles in the TnT negative population, nor for
cardiac death in the total and TnT positive population. The
results remained statistically nonsignificant in the multi-
variable analysis for all groups. The quartile univariate and
multivariable results are presented in Table 4.
In the univariate analysis of continuous 25(OH)D values
in the total population, the HRs for total mortality and
cardiac death were 0.99 (95% CI, 0.98–1.00), 𝑃 = 0.035,
and 0.99 (95% CI, 0.98–1.00), 𝑃 = 0.060, respectively. In the
univariate analysis of the TnT positive population, the HRs
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Table 3: (a) Baseline characteristics of the female population arranged according to the quartiles of 25(OH)D. (b) Baseline characteristics of
the male population arranged according to the quartiles of 25(OH)D.
(a)
Characteristics 𝑛 (%) Quartiles of 25(OH)D 𝑃 value
Q1 Q2 Q3 Q4
25(OH)D (nmol/L)∗ 28.8 ± 5.6 43.2 ± 3.9 55.6 ± 3.4 76.1 ± 12.3 <0.001
25(OH)D (ng/mL)∗ 11.5 ± 2.2 17.3 ± 1.6 22.2 ± 1.4 30.4 ± 4.9 <0.001
Age, years∗ 75.5 ± 14.3 75.8 ± 12.9 75.0 ± 12.1 70.9 ± 12.8 0.058
Smoking status, 𝑛 (%) 0.384
Current smoker, 𝑛 (%) 18 (21.7) 14 (16.7) 10 (11.9) 17 (20.2)
Past smoker, 𝑛 (%) 13 (15.7) 21 (25.0) 17 (20.2) 21 (25.0)
Never smoked, 𝑛 (%) 52 (62.7) 49 (58.3) 57 (67.9) 46 (54.8)
Angina pectoris, 𝑛 (%) 44 (53.0) 45 (53.6) 39 (46.3) 39 (46.4) 0.663
CHF, 𝑛 (%)
Killip class 2–4 43 (51.8) 26 (31.0) 20 (23.8) 17 (20.2) <0.001
History of previous MI, 𝑛 (%) 30 (36.1) 25 (29.8) 25 (29.8) 22 (26.2) 0.567
CABG, 𝑛 (%) 6 (7.2) 3 (3.6) 8 (9.5) 3 (3.6) 0.279
PCI, 𝑛 (%) 1 (1.2) 2 (2.4) 7 (8.3) 8 (9.5) 0.035
Hypertension, 𝑛 (%) 41 (49.4) 39 (46.4) 40 (47.6) 37 (44.4) 0.917
History of DM 1, 𝑛 (%) 1 (1.2) 1 (1.2) 0 (0.0) 1 (1.2) 0.798
History of DM 2, 𝑛 (%) 11 (13.3) 12 (14.3) 13 (15.5) 9 (10.7) 0.828
STEMI, 𝑛 (%) 11 (13.3) 7 (8.3) 3 (3.6) 7 (8.3) 0.164
TnT release, 𝑛 (%) 46 (55.4) 40 (47.6) 42 (50.0) 34 (40.5) 0.277
eGFR (𝜇mol L−1)∗ 52.3 ± 18.4 54.9 ± 17.4 53.9 ± 17.8 58.9 ± 15.1 0.079
Cholesterol/statin, 𝑛 (%) 43 (51.8) 46 (54.8) 45 (53.6) 45 (53.6) 0.985
Beta-blocker, 𝑛 (%) 33 (39.8) 32 (38.1) 38 (45.2) 23 (27.4) 0.112
Known CHD, 𝑛 (%) 59 (71.1) 56 (66.7) 56 (66.7) 50 (59.5) 0.465
BMI (kg/m2)∗ 25.4 ± 4.8 25.5 ± 4.6 25.2 ± 5.2 24.9 ± 4.0 0.886
BNP quartiles 0.094
Q1 17 (20.7) 20 (25.0) 17 (21.5) 27 (33.8)
Q2 19 (23.2) 23 (28.8) 20 (25.3) 19 (23.8)
Q3 15 (18.3) 21 (26.3) 23 (29.1) 21 (26.3)
Q4 31 (37.8) 16 (20.0) 19 (24.1) 13 (16.3)
hsCRP quartiles 0.995
Q1 20 (24.1) 19 (22.6) 21 (25.0) 24 (28.6)
Q2 21 (25.3) 20 (23.8) 22 (26.2) 20 (23.8)
Q3 21 (25.3) 22 (26.2) 19 (22.6) 22 (26.2)
Q4 21 (25.3) 23 (27.4) 22 (26.2) 18 (21.4)
∗Mean ± SD.
SD, standard deviation; 25(OH)D, 25-hydroxyvitamin D; CHF, congestive heart failure; MI, myocardial infarction; CABG, coronary artery bypass grafting;
PCI, percutaneous coronary intervention; DM, diabetes mellitus; STEMI, ST-elevation myocardial infarction; TnT, troponin T; eGFR, estimated glomerular
filtration rate; CHD, coronary heart disease; BMI, body mass index; BNP, B-type natriuretic peptide; hsCRP, high sensitivity C-reactive protein.
(b)
Characteristics 𝑛 (%) Quartiles of 25(OH)D 𝑃 value
Q1 Q2 Q3 Q4
25(OH)D (nmol/L)∗ 31.7 ± 6.0 46.3 ± 3.0 57.4 ± 3.8 79.9 ± 13.7 <0.001
25(OH)D (ng/mL)∗ 12.7 ± 2.4 18.5 ± 1.2 23.0 ± 1.5 32.0 ± 5.5 <0.001
Age, years∗ 63.6 ± 15.3 66.0 ± 16.3 67.8 ± 12.9 68.6 ± 12.3 0.024
Smoking status, 𝑛 (%) 0.211
Current smoker, 𝑛 (%) 53 (40.5) 44 (33.6) 37 (28.0) 34 (26.0)
Past smoker, 𝑛 (%) 53 (40.5) 58 (44.3) 67 (50.8) 63 (48.1)
Never smoked, 𝑛 (%) 25 (19.1) 29 (22.1) 28 (21.2) 34 (26.0)
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(b) Continued.
Characteristics 𝑛 (%) Quartiles of 25(OH)D 𝑃 value
Q1 Q2 Q3 Q4
Angina pectoris, 𝑛 (%) 46 (35.1) 48 (36.6) 60 (45.5) 54 (41.2) 0.306
CHF, 𝑛 (%)
Killip Class 2–4 42 (32.1) 21 (16.0) 32 (24.2) 31 (23.7) 0.026
History of previous MI, 𝑛 (%) 50 (38.2) 46 (35.1) 45 (34.1) 44 (33.6) 0.867
CABG, 𝑛 (%) 18 (13.7) 14 (10.7) 16 (12.1) 19 (14.5) 0.795
PCI, 𝑛 (%) 19 (14.5) 17 (13.0) 18 (13.6) 15 (11.5) 0.903
Hypertension, 𝑛 (%) 44 (33.6) 45 (34.4) 56 (42.4) 59 (45.0) 0.141
History of DM 1, 𝑛 (%) 1 (0.8) 1 (0.8) 1 (0.8) 2 (1.5) 0.894
History of DM 2, 𝑛 (%) 25 (19.1) 14 (10.7) 19 (14.4) 8 (6.1) 0.013
STEMI, 𝑛 (%) 21 (16.0) 28 (21.4) 28 (21.2) 23 (17.6) 0.610
TnT release, 𝑛 (%) 73 (55.7) 74 (56.5) 76 (57.6) 81 (61.8) 0.754
eGFR (𝜇mol L−1)∗ 70.5 ± 21.7 67.0 ± 21.0 68.1 ± 20.6 65.8 ± 21.7 0.312
Cholesterol/statin, 𝑛 (%) 57 (43.5) 62 (47.3) 65 (49.2) 61 (46.6) 0.826
Beta-blocker, 𝑛 (%) 49 (37.4) 44 (33.6) 44 (33.3) 45 (34.4) 0.894
Known CHD, 𝑛 (%) 80 (61.1) 77 (58.8) 85 (64.4) 79 (60.3) 0.817
BMI (kg/m2)∗ 26.1 ± 3.9 26.6 ± 4.9 26.0 ± 3.4 25.0 ± 3.5 0.014
BNP quartiles 0.545
Q1 29 (23.4) 35 (27.3) 27 (21.1) 36 (29.5)
Q2 30 (24.2) 30 (23.4) 39 (30.5) 27 (22.1)
Q3 30 (24.2) 27 (21.1) 36 (28.1) 31 (25.4)
Q4 35 (28.2) 36 (28.1) 26 (20.3) 28 (23.0)
hsCRP Quartiles 0.904
Q1 30 (22.9) 33 (25.2) 32 (24.2) 36 (27.5)
Q2 28 (21.4) 31 (23.7) 35 (26.5) 36 (27.5)
Q3 37 (28.2) 34 (26.0) 35 (26.5) 27 (20.6)
Q4 36 (27.5) 33 (25.2) 30 (22.7) 32 (24.4)
∗Mean ± SD.
SD, standard deviation; 25(OH)D, 25-hydroxyvitamin D; CHF, congestive heart failure; MI, myocardial infarction; CABG, coronary artery bypass grafting;
PCI, percutaneous coronary intervention; DM, diabetes mellitus; STEMI, ST-elevation myocardial infarction; TnT, troponin T; eGFR, estimated glomerular
filtration rate; CHD, coronary heart disease; BMI, body mass index; BNP, B-type natriuretic peptide; hsCRP, high sensitivity C-reactive protein.
for total mortality and cardiac death were 0.99 (95% CI,
0.99–1.00), 𝑃 = 0.012, and 0.99 (95% CI, 0.98–1.00), 𝑃 =
0.055, respectively. The remaining continuous univariate and
multivariable results are shown in Table 5.
3.2. 2-Year Gender Analysis. In the univariate quartile anal-
ysis of total and cardiac mortality in the female population,
the HRs for 25(OH)D in Q4 as compared to Q1 were 0.43
(95% CI, 0.19–0.94), 𝑃 = 0.035, and 0.35 (95% CI, 0.13–
0.98), 𝑃 = 0.046, respectively. No difference in the HR
was found between the 25(OH)D quartiles in males. The
25(OH)D quartiles’ HRs for SCD were not significant in
either the univariate or multivariable models. The quartile
univariate and multivariable results are presented in Table 4.
In the univariate analysis of continuous 25(OH)D values
in the female population, the HRs for total mortality and
cardiac death were 0.98 (95% CI, 0.97–1.00), 𝑃 = 0.023,
and 0.98 (95% CI, 0.97–1.00), 𝑃 = 0.044, respectively. The
continuous univariate andmultivariable results are presented
in Table 5.
3.3. 7-Year Follow-Up. At 7-year follow-up, data collection
was restricted to total mortality. During this period 327 (180
men and 147 women) patients had died. The Kaplan-Meier
curve for survival is shown in Figure 1. In the TnT positive
group, 216 patients (46%) died, as shown in Figure 2.
In the univariate quartile analysis of all-cause mortality
in the total population and in the TnT positive patient popu-
lation, the HRs for 25(OH)D in Q4 as compared to Q1 were
0.66 (95% CI, 0.48–0.89), 𝑃 = 0.007, and 0.60 (95% CI, 0.41–
0.87), 𝑃 = 0.008, respectively. No difference in mortality was
found amongst the 25(OH)D quartiles in the TnT negative
population.The results were statistically nonsignificant in the
multivariable analysis for all groups. The quartile univariate
and multivariable results are presented in Table 4.
In the univariate analysis of continuous 25(OH)D values
in the total population and in the TnT positive patient
population, the HRs for total mortality were 0.99 (95%
CI, 0.99–1.00), 𝑃 = 0.026, and 0.99 (95% CI, 0.98–1.00),
𝑃 = 0.002, respectively. The continuous univariate and
multivariable results are presented in Table 5.
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Table 4: The univariate and multivariable HRs (95% CI) for quartiles of 25(OH)D.
2-year follow-up 7-year follow-up
Univariate analysis Multivariable analysis∗ Univariate analysis Multivariable analysis∗
Total population
Total mortality 0.61 (0.37–1.00)
𝑃 = 0.05
0.79 (0.45–1.40)
𝑃 = 0.40
0.66 (0.48–0.89)
𝑃 = 0.008
0.79 (0.57–1.09)
𝑃 = 0.15
Cardiac death 0.70 (0.37–1.34)
𝑃 = 0.29
0.83 (0.40–1.72)
𝑃 = 0.61 NA NA
SCD 0.59 (0.14–2.44)
𝑃 = 0.46
1.28 (0.26–6.37)
𝑃 = 0.76 NA NA
TnT pos. population
Total mortality 0.59 (0.33–1.04)
𝑃 = 0.07
0.82 (0.42–1.61)
𝑃 = 0.56
0.60 (0.41–0.87)
𝑃 = 0.008
0.74 (0.49–1.12)
𝑃 = 0.15
Cardiac death 0.71 (0.36–1.41)
𝑃 = 0.33
1.09 (0.49–2.42)
𝑃 = 0.84 NA NA
SCD 0.58 (0.14–2.44)
𝑃 = 0.46
1.52 (0.30–7.72)
𝑃 = 0.61 NA NA
Females
Total mortality 0.43 (0.19–0.94)
𝑃 = 0.035
0.65 (0.26–1.62)
𝑃 = 0.36
0.51 (0.32–0.83)
𝑃 = 0.006
0.64 (0.38–1.10)
𝑃 = 0.09
Cardiac death 0.35 (0.13–0.98)
𝑃 = 0.046
0.61 (0.19–2.00)
𝑃 = 0.41 NA NA
SCD 0.0 (0.00-0.00)
𝑃 = 0.96 NA NA NA
Males
Total mortality 0.85 (0.46–1.57)
𝑃 = 0.61
0.81 (0.40–1.65)
𝑃 = 0.56
0.82 (0.56–1.24)
𝑃 = 0.36
0.73 (0.47–1.12)
𝑃 = 0.15
Cardiac death 1.09 (0.46–2.56)
𝑃 = 0.85
0.89 (0.32–2.46)
𝑃 = 0.83 NA NA
SCD 0.99 (0.20–4.88)
𝑃 = 0.99
1.92 (0.31–12.1)
𝑃 = 0.49 NA NA
SCD, sudden cardiac death.
∗Adjusted for gender, age, smoking, hypertension, index diagnosis, diabetes mellitus, CHF (defined by Killip-Kimball class at admission; patients in classes 2
to 4 were classified as CHF patients and those in class 1 as non-CHF), history of previous CHD (i.e., history of either angina pectoris, myocardial infarction,
percutaneous coronary intervention, or coronary artery bypass graft), hypercholesterolemia/use of statins, TnT >0.01 ng/mL, eGFR, hsCRP, BNP, body mass
index (kg/m2), and beta-blockers prior to enrolment.
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Figure 1: Kaplan-Meier plots for seven-year total mortality of
25(OH)D quartiles in the total patient population.
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Figure 2: Kaplan-Meier plots for seven-year total mortality of
25(OH)D quartiles in the TnT positive patient population.
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Table 5: The univariate and multivariable HRs (95% CI) for continuous 25(OH)D values.
2-year follow-up 7-year follow-up
Univariate analysis Multivariable analysis∗ Univariate analysis Multivariable analysis∗
Total population
Total mortality 0.99 (0.98–1.00)
𝑃 = 0.035
1.00 (0.99–1.01)
𝑃 = 0.38
0.99 (0.99-1.00)
𝑃 = 0.026
1.00 (0.99-1.00)
𝑃 = 0.23
Cardiac death 0.99 (0.98–1.00)
𝑃 = 0.06
0.99 (0.98–1.01)
𝑃 = 0.29 NA NA
SCD 0.99 (0.97–1.01)
𝑃 = 0.23
1.00 (0.98–1.02)
𝑃 = 0.92 NA NA
TnT pos. population
Total mortality 0.99 (0.99-1.00)
𝑃 = 0.012
0.99 (0.98–1.01)
𝑃 = 0.34
0.99 (0.98–1.00)
𝑃 = 0.002
0.99 (0.99-1.00)
𝑃 = 0.07
Cardiac death 0.99 (0.97–1.00)
𝑃 = 0.055
1.00 (0.98–1.01)
𝑃 = 0.54 NA NA
SCD 0.98 (0.96–1.01)
𝑃 = 0.12
1.0 (0.97–1.02)
𝑃 = 0.74 NA NA
Females
Total mortality 0.98 (0.97–1.00)
𝑃 = 0.023
1.00 (0.98–1.01)
𝑃 = 0.53
0.99 (0.98–1.00)
𝑃 = 0.025
1.00 (0.99–1.01)
𝑃 = 0.53
Cardiac death 0.98 (0.97–1.00)
𝑃 = 0.044
0.99 (0.97–1.01)
𝑃 = 0.45 NA NA
SCD 0.98 (0.95–1.01)
𝑃 = 0.13
0.99 (0.96–1.03)
𝑃 = 0.73 NA NA
Males
Total mortality 1.0 (0.98–1.01)
𝑃 = 0.58
0.99 (0.98–1.01)
𝑃 = 0.40
1.0 (0.99–1.01)
𝑃 = 0.42
0.99 (0.99-1.00)
𝑃 = 0.10
Cardiac death 1.0 (0.98–1.01)
𝑃 = 0.65
0.99 (0.97–1.01)
𝑃 = 0.36 NA NA
SCD 1.0 (0.97–1.03)
𝑃 = 0.99
1.01 (0.98–1.05)
𝑃 = 0.43 NA NA
SCD, sudden cardiac death.
∗Adjusted for gender, age, smoking, hypertension, index diagnosis, diabetes mellitus, CHF (defined by Killip-Kimball class at admission; patients in class 2
to 4 were classified as CHF patients and those in class 1 as non CHF), history of previous CHD (i.e., history of either angina pectoris, myocardial infarction,
percutaneous coronary intervention, or coronary artery bypass graft), hypercholesterolemia/use of statins, TnT >0.01 ng/mL, eGFR, hsCRP, BNP, body mass
index (kg/m2), and beta-blockers prior to enrolment.
Evaluating the influence of diabetes in the total popula-
tion, the univariate analysis at 7-year follow-up revealed a
significant difference in total mortality, 𝑃 < 0.001, not found
in the multivariable analysis.
3.4. 7-Year Gender Analysis. The univariate quartile analysis
showed a statistically significant difference in the HR of Q4
as compared to Q1 of 25(OH)D for total death among females
0.51 (95% CI, 0.32–0.83), 𝑃 = 0.006, but not amongst males.
The KM curve for survival in females is shown in Figure 3.
The difference found in women was no longer significant
in the multivariable analysis. The quartile univariate and
multivariable results are presented in Table 4.
In the univariate analysis of continuous 25(OH)D values
in the female population, the HR for total mortality was 0.99
(95%CI 0.98–1.00),𝑃 = 0.025.The continuous univariate and
multivariable results are presented in Table 5.
3.5. 7-Year Follow-Up of Vitamin D Deficient [<40 nM
(<16 ng/mL)] Patients. There were 232 patients (27%) with
25(OH)D levels below 40 nM (16 ng/mL) and 629 patients
(73%) with 25(OH)D levels above and equal to 40 nM
(16 ng/mL). The univariate HR for total mortality in patients
with 25(OH)D deficiency was 1.43 (95% CI, 1.14–1.81); 𝑃 =
0.002, as compared to subjects without 25(OH)D deficiency
and was still significant in the multivariable model; HR 1.32
(95% CI, 1.04–1.68), 𝑃 = 0.024.
3.6. Seasonal Correlation between Vitamin D and Omega-3
Index. 456 patients (298 men and 158 women) were included
in the seasonal correlation study between 25(OH)D and
omega-3 index. Mean 25(OH)D levels in this subgroup were
50.4 ± 18.2 nM (29.2 ± 7.3 ng/mL) winter-spring and 55.2 ±
20.1 nM (22.1 ± 8.0mg/mL) during the summer-autumn
season;𝑃 = 0.009. Corresponding levels of the omega-3 index
were 6.8(1.9)% and 6.6(1.9)%, respectively; 𝑃 = 0.26. In this
subgroup, there was a strong positive correlation between
25(OH)D and the omega-3 index during both seasons. For
the total population the Pearson’s correlation coefficient was
0.358, 𝑃 < 0.001, during the winter-spring season and 0.199,
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Figure 3: Kaplan-Meier plots for seven-year total mortality of
25(OH)D quartiles in females.
𝑃 = 0.006, during the summer-autumn period, respectively.
The Pearson’s seasonal correlation coefficient for females was
0.380, 𝑃 < 0.001 and 0.183 𝑃 = 0.16, respectively, and for
males 0.347, 𝑃 < 0.001 and 0.205, 𝑃 = 0.022, respectively.
4. Discussion
Our chest pain population was recruited from the southwest-
ern coast of Norway, at a latitude of 58∘N. At this latitude,
the production of cutaneous vitamin D is low in the winter
months during which vitamin D levels depend on other
sources, mainly fish intake.
We divided the population into quartiles of vitamin D
levels, comparing the higher quartiles to the lowest quartile,
and performed univariate and multivariable analyses of
mortality at 2- and 7-year follow-up.
In the univariate quartile analysis at 2-year follow-up of
the total and TnT positive patient population we observed
a trend towards decreased total and cardiac mortality in the
upper as compared to the lower quartile of vitamin D. These
trends approached significant values when applying contin-
uous vitamin D data in the univariate analysis (Table 5). In
the female population, the reduction in total and cardiac
mortality reached statistical significance by both quartile and
continuous univariate analysis.
At 7-year follow-up, both statistical approaches yielded
significant results in the univariate analysis, with reduced
total and cardiacmortality associatedwith increasing vitamin
D levels in the total and TnT positive population, as well as in
the female population, respectively. These and other 7-year
follow-up data are shown in Table 5.
These associations were not present after adjusting for
confounding variables in ourmultivariablemodel. In contrast
to studies in which multivariable models have demonstrated
a U-shape or reverse J-shape mortality curve across quintiles
[4] and quartiles [5] of vitamin D, the statistically nonsignif-
icant results in our multivariable quartile analysis precluded
a similar evaluation. However, the univariate quartile hazard
ratios in our ACS population showed a similar pattern to that
of the above studies [4, 5], in which subjects were enrolled
from a general elderly population, with the highest age (>75
years) in the study by Jia et al. [4] as compared to 69.6 ± 14.4
years in our study. In general, the vitamin D values in our
patients were higher than in the two other studies, with the
lowest quartile in our study comparable to that of second
and third quintiles in the study by Jia et al. [4] and to the
second quartile in the study by Visser et al. [5]. Furthermore,
less interquartile differences in morbidity and mortality in
our study may be related to a tighter range of vitamin D
values.
In a previous report from our group we obtained more
definitive results investigating a population in Northern
Argentina located at a latitude of 24∘ and at an altitude
more than 1000m above sea level. In the latter population,
the prognostic utility of vitamin D in the female population
remained highly significant after correcting for confounding
factors, which statistically may be due to a larger proportion
of females and more events in this subgroup. Similar results
have been obtained in a German study by Karakas et al. [22].
However, in that study they included 1783 healthy middle-
aged subjects of both gender with a follow-up of eleven
years during which they identified 298 combined CHD cases,
whereas we investigated total and cardiac death in chest pain
patients with suspected ACS.
In our Norwegian as compared to our Argentinean study
[16] levels of vitamin D were similar in the lowest quartile
(30.5 ± 5.9 nM versus 30.7 ± 5.6 nM) of the total populations.
Levels were also similar in Q2 andQ3, but higher in Q4 in the
Norwegian population (78.6±13.2 nMversus 72.9±11.1 nM).
This was an unexpected finding, as the geographic locations
are different with respect to sun exposure.
We have previously [23] published data suggesting that
vitamin D status may be related to socioeconomic factors,
implying that low vitamin D levels in that setting may
behave as a secondary risk marker. In our present population
the quartile levels of vitamin D were clearly related to the
difference in dietary capture of vitamin D, as demonstrated
by a monotonic increase in omega-3 values from lowest to
highest quartile of vitamin D, as shown in Table 2.
Based on our observational data, reduced vitamin D
levels may not only be regarded as a marker of morbidity in
women as compared to men but may also reflect a gender
difference in serumvitaminDconcentration.Themechanism
for this difference is not obvious, although a female hormonal
interaction has been noted, with levels of vitamin D and
progesterone/estrogen being inversely correlated [24].
Optimal levels of 25(OH)Dare still under debate. Accord-
ing to Ross et al. [20], levels of at least 50 nM will meet the
needs of at least 97.5% of the population, whereas the median
vitamin D concentration in the general population will be
above 40 nM. In the present study, we have investigated
the significance of vitamin D levels < 40 nM in relation to
outcome. Below 40 nM (16 ng/mL), vitamin D behaved as an
independent predictor for total death both in the univariate
and multivariable analysis. As vitamin D deficiency was
found to be an independent risk factor at levels below 40 nM,
higher levels may reflect an overall healthier lifestyle andmay
not in themselves be causally related to outcome.
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In a subpopulation consisting of TnT positive patients,
the correlation between vitamin D and the omega-3 index,
including EPA and DHA, was higher during winter-spring
(𝑟 = 0.358, 𝑃 < 0.001) as compared to the summer-autumn
season (𝑟 = 0.199, 𝑃 = 0.006). As the omega-3 index was
similar in both seasons, this finding may be explained by
an increased utilization of vitamin D in the diet during the
winter season, and the lower correlation during the summer
season may be due to the increased levels of cutaneous
vitamin D production. Our results are in accordance with a
recent publication in which the authors compared levels of
vitaminDobtained from sun exposure versus diet at the same
altitude as in the present study [25].
The association between vitamin D and omega-3, espe-
cially during the winter-spring season, is of interest, as the
diet may be the main source of vitamin D during this period.
Furthermore, the correlation was strongest in women in
whom vitamin D showed less seasonal variation. Thus, due
to its prognostic implication, vitamin D may be involved in
the beneficial effects of fish intake. Therefore, the natural
presence of vitamin D in dietary studies, such as in DART
[26] and in the long-term follow-up study by Kromhout
et al. [27], may have beneficially affected outcome in these
studies, as reflected by the stepwise increase in the omega-3
index from lowest to highest quartile of vitamin D in the
present study. Although reduction in mortality was noted in
the omega-3 arm of the GISSI studies [28, 29], some of the
other megatrials also applying a purified omega-3 compound
have not shown a reduction in mortality, as noted in a meta-
analysis by Kwak et al. [30], involving 20485 patients with a
history of cardiovascular disease from 14 randomized, double
blind, and placebo controlled studies.
The addition of vitamin D to a purified omega-3 com-
pound is being investigated in the VITAL study (ClinicalTri-
als.gov Identifier: NCT01169259).
Strengths and Limitations. In comparison to other observa-
tional studies enrolling subjects from a general population,
the novelty in this study is related to (1) selection of a
chest pain population with suspected ACS, (2) blood samples
obtained at hospital admission, and (3) categorization of
subjects with and without myocardial injury. In contrast
to many other studies, we have focused not only on total
mortality but also on cardiac death in our selected high
risk population. The strength of our study is mainly related
to the long-term follow-up and the proportion of females
accounting for 39% of the patients. Furthermore, its design
is similar to that of our previously published Argentinean
report based on admitted chest pain patients with suspected
ACS [16], enabling a comparison of western lifestyle and
traditions to that of a South-American population with other
traditions and dietary habits. A larger number of patientsmay
have contributed to more consistent findings in our Argen-
tinean population. However, as power calculations are not
applicable in observational studies, this should be regarded
as a limitation. Also, we did not correct for parathyroid
hormone (PTH), but we do not regard this to be of great
importance, as previous data would indicate that only very
low values of vitamin D will influence the level of PTH [31].
As this is an observational study, unknown confounders may
have been missed.
In conclusion, at long-term follow-up the univariate anal-
ysis demonstrated a statistically significant lower mortality in
the highest as compared to the lowest quartile of vitaminD in
chest pain patients with suspected ACS, especially in females.
Vitamin D was independently related to mortality at levels
below the population median. An increase in the omega-3
index was noted from lowest to highest quartile of vitamin D
and there was a stronger correlation between vitamin D and
the omega-3 index during winter-spring as compared to the
summer-autumn season.
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